News
Sports
Life
Opinion
Business
Advertise
Obituaries
eNewspaper
Legals
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
NewsOK Local Stocks
NewsOK Local Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Axcella Health Inc
(NQ:
AXLA
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EST, Nov 22, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Axcella Health Inc
< Previous
1
2
Next >
Axcella Health Inc. (NASDAQ: AXLA) Leading the Way in Thursday Trading Based on Percentage Gain
September 28, 2023
Via
Investor Brand Network
Axcella Announces Reverse Stock Split Effective September 19, 2023
September 14, 2023
From
Axcella Therapeutics
Via
Business Wire
Axcella Granted Patent for Long COVID Fatigue Treatment
August 29, 2023
From
Axcella Therapeutics
Via
Business Wire
Axcella Reports Second Quarter Financial Results and Provides Business Update
August 03, 2023
From
Axcella Therapeutics
Via
Business Wire
Axcella Reports First Quarter Financial Results and Provides Business Update
May 04, 2023
From
Axcella Therapeutics
Via
Business Wire
Axcella Announces Two Oral Presentations on AXA1125 for Long COVID Fatigue at ECCMID 2023
April 17, 2023
From
Axcella Therapeutics
Via
Business Wire
Axcella Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
March 30, 2023
From
Axcella Therapeutics
Via
Business Wire
Axcella Announces FDA IND Clearance Supporting Regulatory Path to Registration of AXA1125 for Long COVID Fatigue
February 15, 2023
From
Axcella Therapeutics
Via
Business Wire
Axcella Therapeutics to Participate in the SVB Securities’ 2023 Global Biopharma Conference
February 09, 2023
From
Axcella Therapeutics
Via
Business Wire
Axcella Announces Regulatory Path to Registration of AXA1125 for Long COVID Fatigue
January 23, 2023
From
Axcella Therapeutics
Via
Business Wire
Axcella Announces Program Reprioritization and Corporate Restructuring
December 14, 2022
From
Axcella Therapeutics
Via
Business Wire
Axcella to Present at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting
November 03, 2022
From
Axcella Therapeutics
Via
Business Wire
Axcella Reports Third Quarter Financial Results and Provides Business Update
November 01, 2022
From
Axcella Therapeutics
Via
Business Wire
Axcella Therapeutics to Report Third Quarter 2022 Financial Results on November 1, 2022
October 27, 2022
From
Axcella Therapeutics
Via
Business Wire
Axcella Therapeutics to Participate in the H.C. Wainwright 6th Annual NASH Investor Conference
October 14, 2022
From
Axcella Therapeutics
Via
Business Wire
Axcella Therapeutics Announces $34.2 Million Registered Direct Offering of Common Stock Priced At The Market: Appoints Two New Board Members
October 13, 2022
From
Axcella Therapeutics
Via
Business Wire
Axcella Announces Positive Interim Data from Phase 2b EMMPACT Study of AXA1125 in Nonalcoholic Steatohepatitis (NASH)
September 29, 2022
From
Axcella Therapeutics
Via
Business Wire
Axcella Therapeutics to Participate in the H.C. Wainwright Global Investment Conference
September 12, 2022
From
Axcella Therapeutics
Via
Business Wire
Axcella Reports Second Quarter Financial Results and Provides Business Update
August 12, 2022
From
Axcella Therapeutics
Via
Business Wire
Axcella Announces Highly Promising Results from Phase 2a Placebo Controlled Clinical Trial for Long COVID
August 02, 2022
From
Axcella Therapeutics
Via
Business Wire
Axcella Announces Completion of Enrollment of Clinical Trial for Long COVID and Has Prioritized its Clinical Portfolio
May 26, 2022
From
Axcella Therapeutics
Via
Business Wire
Axcella Therapeutics to Participate in the H.C. Wainwright Global Investment Conference
May 19, 2022
From
Axcella Therapeutics
Via
Business Wire
Axcella Reports First Quarter Financial Results and Provides Business Update
May 05, 2022
From
Axcella Therapeutics
Via
Business Wire
Axcella Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
March 30, 2022
From
Axcella Therapeutics
Via
Business Wire
Axcella to Report Fourth Quarter and Year End 2021 Financial Results on March 30, 2022
March 23, 2022
From
Axcella Therapeutics
Via
Business Wire
Axcella Therapeutics Announces $25 Million Registered Direct Offering of Common Stock Priced At The Market
March 16, 2022
From
Axcella Therapeutics
Via
Business Wire
Axcella Therapeutics Announces FDA Fast Track Designation for AXA1125 in NASH
February 14, 2022
From
Axcella Therapeutics
Via
Business Wire
Axcella Therapeutics to Participate in the SVB Leerink Global Healthcare Conference
February 10, 2022
From
Axcella Therapeutics
Via
Business Wire
Axcella Therapeutics Announces Appointment of New Chief Financial Officer
February 07, 2022
From
Axcella Therapeutics
Via
Business Wire
Axcella Therapeutics Details Clinical and Operational Milestones for 2022
January 06, 2022
From
Axcella Therapeutics
Via
Business Wire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.